MCM
IOVA icon

MAI Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

MAI Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69K Buy
16,580
+12,571
+314% +$47.8K ﹤0.01% 1949
2026
Q1 		$14.1K Buy
4,009
+868
+28% +$2.78K ﹤0.01% 2971
2025
Q4 		$8.57K Buy
3,141
+1,040
+50% +$2.41K ﹤0.01% 2913
2025
Q3 		$4.56K Buy
2,101
+1,000
+91% +$2.36K ﹤0.01% 3055
2025
Q2 		$1.89K Hold
1,101
– – ﹤0.01% 3442
2025
Q1 		$3.67K Hold
1,101
– – ﹤0.01% 2821
2024
Q4 		$8.15K Buy
+1,101
New +$10.2K ﹤0.01% 2604

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

MAI Capital Management's IOVA Position: Q2 2026 in Review

MAI Capital Management increased its Iovance Biotherapeutics (IOVA) stake by 314% in Q2 2026, buying an estimated $47.8K and bringing the position to 16,580 shares worth $69K. The position accounts for ﹤0.01% of the portfolio, ranked #1949.

MAI Capital Management first reported a position in IOVA in Q4 2024 and has held it in 7 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • MAI Capital Management held 16,580 shares of Iovance Biotherapeutics worth $69K as of Q2 2026.
  • MAI Capital Management bought 12,571 Iovance Biotherapeutics shares in Q2 2026, an estimated $47.8K.
  • Iovance Biotherapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #1949 holding.
  • MAI Capital Management first reported a position in Iovance Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.